
Rick Klausner's crew of T cell specialists wraps $425M IPO, hitting Nasdaq alongside Verve, Molecular Partners
It’s harvest day for a pair of biotech startups with lofty goals to break new ground in cancer and coronary heart disease — and their high-profile founders.
Rick Klausner’s Lyell Immunopharma and Sek Kathiresan’s Verve Therapeutics have both priced their IPOs, raising $425 million and $266.7 million, respectively. Neither are in the clinic yet, but if their newly gained valuations are any indication, there is plenty of appetite for the kind of animal data and bold approaches they offer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.